Month: September 2022

Press release Holmens Kanal 2 – 12DK-1092 København KTel. +45 45 14 00 00 16 September 2022Change of ownership in merger of mobile payment providers Following a dialogue with the European Commission’s Directorate-General for Competition, the owner banks behind the planned merger of the three mobile payment providers MobilePay, Vipps and Pivo have reached the decision that OP Financial Group in Finland will not be a co-owner and that Pivo will not be part of the merger. Towards the end of the second quarter of 2021, Danske Bank announced an agreement with OP Financial Group in Finland and the consortium of banks behind Vipps in Norway to merge the three mobile payment providers MobilePay, Vipps and Pivo. During this summer, however, the Commission expressed concerns about both MobilePay and Pivo being part of the merger, since...

August 2022 Sales price Group sales prices development as followsQ1           2017       1,24 EUR/kg live weight (Jan 1,23 EUR – Feb 1,24 EUR – Marts 1,26 EUR) Q2           2017       1,41 EUR/kg live weight (Apr 1,43 EUR – May 1,41 EUR – June 1,39 EUR) Q3           2017       1,30 EUR/kg live weight (July 1,32 EUR – Aug 1,30 EUR – Sept 1,29 EUR) Q4           2017       1,13 EUR/kg live weight (Oct 1,17 EUR – Nov 1,12 EUR – Dec 1,11 EUR) Q1           2018       1,09 EUR/kg live weight (Jan 1,07 EUR – Feb 1,08 EUR – Marts 1,12 EUR) Q2           2018       1,17 EUR/kg live weight (April 1,18 EUR – May 1,15 EUR – June 1,18 EUR) Q3           2018       1,19 EUR/kg live weight (July 1,19 EUR, August 1,18 EUR, September 1,19) Q4           2018       1,10 EUR/kg live weight (Oct 1,11 EUR – Nov 1,12 EUR – Dec 1,07 EUR) Q1           2019      ...

COMPANY HONORED FOR ITS INITIATIVES TO ADDRESS CLIMATE CHANGEWind Farm Image of the company’s wind farm.HORSHAM, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) — Bimbo Bakeries USA, Inc., a proud Grupo Bimbo business, has received a 2022 Green Power Leadership Award from the U.S. Environmental Protection Agency (EPA) for outstanding clean energy initiatives and impact on the green power market. For more than 20 years, EPA’s annual Green Power Leadership Awards have recognized America’s leading green power users for their commitment to using renewable electricity and advancing the nation’s green power market. EPA presented Bimbo Bakeries USA with a Green Power Partner of the Year award at the 2022 Renewable Energy Markets Conference on September 15, 2022. Bimbo Bakeries USA is currently using more than 490 million kWh of green power...

HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 29,809,471 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase...

New role optimizes resources in cultivation, production and supply chain for maximum output TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) — Entourage Health Corp. (TSX-V:ENTG) (OTCQX:ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products is pleased to announce the appointment of James Afara as the Company’s Chief Operating Officer (COO). A results-driven leader with an exceptional track record, James brings over 15 years of operations and supply chain experience to Entourage, serving most recently as its Senior Vice President of Strategic Sourcing, Quality Assurance and Cultivation. His promotion comes at a pivotal time as the Company integrates all functional teams in cultivation, tissue culture, production, operations and supply chain under one leader, to align core...

Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of NTLA-2002 led to a 65% and 92% mean plasma kallikrein reduction at 25 mg and 75 mg doses, respectively, at week eight HAE attacks were reduced by 91% in the 25 mg dose cohort through week 16; two of three patients remain attack free since treatment with third patient attack free since week 10 through latest follow-up NTLA-2002 was generally well-tolerated at both dose levels Intellia plans to initiate the Phase 2 dose-expansion portion of the study in 1H 2023 Intellia to host investor event today, Friday, September 16, at 8:00 a.m. ETCAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading...

UAB “Atsinaujinančios Energetikos Investicijos” (the Company), legal entity code: 304213372, registered at: Jogailos str. 4, 01116, Vilnius, the Republic of Lithuania. The total nominal value of the issued notes of the Company: EUR 40,000,000; ISIN code: LT0000405938. The Company informs that, in accordance with the requirements of Transparency Directive 2004/109/EC, The Republic of Lithuania is its Home Member State. Contact person for further information: Tomas Milašauskas Manager of the Investment Company tomas.milasauskas@lordslb.lt www.lordslb.lt/AEI_green_bonds

Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28 NTLA-2001 was generally well-tolerated at both dose levels Intellia to discuss data at investor event today, Friday, September 16, at 8:00 a.m. ETCAMBRIDGE, Mass. and TARRYTOWN, N.Y., Sept. 16, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis. The interim data include 12 adult patients with ATTR amyloidosis with cardiomyopathy...